Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Role of TPMT and ITPA variants in mercaptopurine disposition

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Selection criteria for assembling a pediatric cancer predisposition syndrome gene panel

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Parenthood among men diagnosed with cancer in childhood and early adulthood: trends over time in a Danish national cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genomforskningsprojekt påviser TP53-mutation hos en pige med rabdomyosarkom

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Play interventions for paediatric patients in hospital: a scoping review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

PURPOSE: Osteonecrosis is a burdensome treatment-related toxicity that is mostly diagnosed during or soon after 6-mercaptopurine (6MP)/methotrexate (MTX) maintenance therapy for acute lymphoblastic leukemia (ALL), possibly indicating a pathogenic role of these drugs.

METHODS: We prospectively registered symptomatic osteonecrosis during treatment of 1234 patients aged 1.0-45.9 years treated according to the Nordic Society of Hematology and Oncology (NOPHO) ALL2008 protocol. MTX/6MP metabolites were measured as part of the NOPHO ALL2008 maintenance therapy study.

RESULTS: After a median follow-up of 5.6 years [interquartile range (IQR) 3.6-7.5], 68 patients had been diagnosed with symptomatic osteonecrosis. The cumulative incidence was 2.7% [95% confidence interval (CI) 1.6-3.8%] for patients aged < 10 years, 14.9% (95% CI 9.7-20.2%) for patients aged 10.0-17.9 years, and 14.4% (95% CI 8.0-20.8%) for patients aged ≥ 18 years. The median time from diagnosis of ALL to diagnosis of osteonecrosis in these age groups was 1.0 year (IQR 0.7-2.0), 2.0 years (IQR 1.1-2.4), and 2.2 years (IQR 1.8-2.8), respectively (p = 0.001). With 17,854 blood samples available for MTX and 6MP metabolite analysis, neither erythrocyte levels of 6-thioguanine (TG) nucleotides (p > 0.99), methylated 6MP metabolites (p = 0.37), MTX polyglutamates (p = 0.98) nor DNA-TG (p = 0.53) were significantly associated with the hazard of osteonecrosis in Cox models stratified by the three age groups and adjusted for sex.

CONCLUSION: Maintenance therapy intensity determined by 6MP and MTX metabolites was not associated with the risk of developing osteonecrosis in the NOPHO ALL2008 cohort.

Original languageEnglish
JournalCancer Chemotherapy and Pharmacology
Volume88
Issue number5
Pages (from-to)911-917
Number of pages7
ISSN0344-5704
DOIs
Publication statusE-pub ahead of print - 18 Jun 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

    Research areas

  • Acute lymphoblastic leukemia, Maintenance, Mercaptopurine, Osteonecrosis, Pharmacokinetics

ID: 66495129